What is HC Wainwright’s Estimate for DNTH FY2026 Earnings?

Posted by Stanley Muller on Nov 10th, 2026

Dianthus Therapeutics, Inc. (NASDAQ:DNTH – Free Report) – Equities research analysts at HC Wainwright upped their FY2026 earnings per share (EPS) estimates for Dianthus Therapeutics in a report released on Friday, November 6th. HC Wainwright analyst S. Ramakanth now forecasts that the company will post earnings of ($3.62) per share for the year, up from their prior forecast of ($3.87). HC Wainwright has a “Buy” rating and a $158.00 price objective on the stock. The consensus estimate for Dianthus Therapeutics’ current full-year earnings is ($3.60) per share. HC Wainwright also issued estimates for Dianthus Therapeutics’ Q4 2026 earnings at ($1.06) EPS, Q1 2027 earnings at ($1.12) EPS, Q2 2027 earnings at ($1.16) EPS, Q3 2027 earnings at ($1.21) EPS, Q4 2027 earnings at ($1.26) EPS, FY2027 earnings at ($4.76) EPS, FY2028 earnings at ($5.41) EPS, FY2029 earnings at ($5.42) EPS and FY2030 earnings at $2.35 EPS.

Dianthus Therapeutics (NASDAQ:DNTH – Get Free Report) last released its quarterly earnings data on Wednesday, November 4th. The company reported ($0.81) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.94) by $0.13. Dianthus Therapeutics had a negative return on equity of 21.15% and a negative net margin of 7,436.50%. The firm had revenue of $1.21 million for the quarter, compared to analyst estimates of $0.46 million.

Other equities research analysts have also recently issued research reports about the company. Citigroup initiated coverage on Dianthus Therapeutics in a research note on Friday, September 4th. They issued a “buy” rating and a $156.00 price target on the stock. Raymond James Financial reaffirmed a “strong-buy” rating and set a $134.00 price target on shares of Dianthus Therapeutics in a report on Thursday. Wedbush lifted their price objective on shares of Dianthus Therapeutics from $105.00 to $122.00 and gave the stock an “outperform” rating in a research report on Wednesday, August 5th. Truist Financial upped their price objective on shares of Dianthus Therapeutics from $110.00 to $128.00 and gave the company a “buy” rating in a report on Thursday, August 6th. Finally, JPMorgan Chase & Co. assumed coverage on shares of Dianthus Therapeutics in a report on Friday, September 11th. They issued an “overweight” rating and a $135.00 price objective on the stock. Two investment analysts have rated the stock with a Strong Buy rating, thirteen have given a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat.com, Dianthus Therapeutics currently has an average rating of “Buy” and a consensus target price of $128.77.

Get Our Latest Analysis on Dianthus Therapeutics

Dianthus Therapeutics Trading Up 4.6%

Shares of NASDAQ DNTH opened at $90.00 on Tuesday. Dianthus Therapeutics has a 12 month low of $34.29 and a 12 month high of $117.88. The stock has a 50 day moving average of $89.73 and a 200-day moving average of $85.78. The company has a market capitalization of $4.93 billion, a P/E ratio of -22.56 and a beta of 1.47.

Institutional Trading of Dianthus Therapeutics

Hedge funds have recently added to or reduced their stakes in the company. IFG Advisory LLC boosted its stake in Dianthus Therapeutics by 19.1% in the 3rd quarter. IFG Advisory LLC now owns 6,000 shares of the company’s stock valued at $528,000 after purchasing an additional 961 shares during the period. Fisher Asset Management LLC grew its holdings in Dianthus Therapeutics by 1,068.4% in the 3rd quarter. Fisher Asset Management LLC now owns 272,863 shares of the company’s stock valued at $24,026,000 after buying an additional 249,510 shares in the last quarter. Fifth Third Bancorp increased its position in Dianthus Therapeutics by 23.6% during the 3rd quarter. Fifth Third Bancorp now owns 676 shares of the company’s stock worth $60,000 after buying an additional 129 shares during the period. Keybank National Association OH increased its position in Dianthus Therapeutics by 24.1% during the 3rd quarter. Keybank National Association OH now owns 4,355 shares of the company’s stock worth $383,000 after buying an additional 845 shares during the period. Finally, Allspring Global Investments Holdings LLC lifted its holdings in shares of Dianthus Therapeutics by 4.5% during the third quarter. Allspring Global Investments Holdings LLC now owns 4,851 shares of the company’s stock worth $428,000 after buying an additional 209 shares in the last quarter. 47.53% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling at Dianthus Therapeutics

In other news, EVP Simrat Randhawa sold 23,124 shares of the business’s stock in a transaction that occurred on Tuesday, September 1st. The stock was sold at an average price of $106.41, for a total transaction of $2,460,624.84. Following the completion of the sale, the executive vice president owned 4,000 shares in the company, valued at $425,640. The trade was a 85.25% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, CAO Edward Carr sold 20,000 shares of the business’s stock in a transaction that occurred on Thursday, September 17th. The stock was sold at an average price of $101.38, for a total value of $2,027,600.00. Following the sale, the chief accounting officer owned 20,000 shares of the company’s stock, valued at approximately $2,027,600. This represents a 50.00% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 45,902 shares of company stock valued at $4,814,779 in the last three months. 3.02% of the stock is currently owned by company insiders.

Trending Headlines about Dianthus Therapeutics

Here are the key news stories impacting Dianthus Therapeutics this week:

Positive Sentiment: HC Wainwright raised its estimates for 2026 and 2027, projecting smaller losses than before, and also reduced its estimated 2028 loss. The firm maintained a Buy rating and a $158 price target. MarketBeat analyst estimate report
Positive Sentiment: A Zacks report said analysts’ average price target implied 61.23% potential upside and noted that upward earnings-estimate revisions can be a constructive signal. It cautioned, however, that price targets have limited predictive reliability. Zacks analyst price-target report
Negative Sentiment: HC Wainwright sharply cut its longer-range forecasts: its 2029 estimate shifted from a small profit to a loss, and its 2030 profit estimate fell from $10.75 to $2.35 per share. Those revisions temper the more favorable near-term changes. MarketBeat analyst estimate report

About Dianthus Therapeutics

(Get Free Report)

Dianthus Therapeutics is a clinical-stage biotechnology company developing medicines for autoimmune and inflammatory diseases involving the complement system, a part of the immune system. The company’s research focuses on selectively targeting complement activity that contributes to disease.